{"id":953415,"date":"2026-04-21T10:18:13","date_gmt":"2026-04-21T14:18:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/"},"modified":"2026-04-21T10:18:13","modified_gmt":"2026-04-21T14:18:13","slug":"aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/","title":{"rendered":"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting"},"content":{"rendered":"
\n

DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract \u201cEarly results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)\u201d at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/a>, to take place May 29 – June 2, 2026, in Chicago, IL. \u00a0<\/p>\n\n\n\n\n\n\n\n\n\n
\n
\n Presentation Details:<\/u>
\n <\/strong>
\n \n <\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\nEarly results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)<\/td>\n<\/tr>\n
\n Presenting author:<\/strong>\n <\/td>\nShiraj Sen, MD. PhD., NEXT Oncology Dallas, TX<\/td>\n<\/tr>\n
\n Session:<\/strong>\n <\/td>\nPoster Session – Developmental Therapeutics\u2014Molecularly Targeted Agents and Tumor Biology<\/td>\n<\/tr>\n
\n Date and Time:<\/strong>\n <\/td>\nMay 30, 2026, 1:30 PM-4:30 PM CDT<\/td>\n<\/tr>\n
\n Poster Board:<\/strong>\n <\/td>\n244<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

For more information on the ACESOT-1051 trial, refer to ClinicalTrials.gov\u00a0NCT06260514<\/a>.<\/p>\n

\n About Aprea<\/strong>\n <\/p>\n

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea\u2019s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The company\u2019s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at\u00a0www.aprea.com<\/a>.<\/p>\n

The Company may use, and intends to use, its investor relations website at\u00a0https:\/\/ir.aprea.com\/<\/a>\u00a0as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.<\/p>\n

\n
\n Forward-Looking Statement<\/em>
\n <\/strong>\n <\/p>\n

\n Certain information contained in this press release includes \u201cforward-looking statements\u201d, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as \u201cfuture,\u201d \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201ctargeting,\u201d \u201cconfidence,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201clikely,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials\u00a0(including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and our ability to predict clinical outcomes based on such preclinical and early clinical results, our ability to continue as a going concern, and the other risks, uncertainties, and other factors described under \u201cRisk Factors,\u201d \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d and elsewhere in the documents we file with the\u00a0U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.<\/em>\n <\/p>\n

\n Investor Contact:<\/strong>\n <\/p>\n

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract \u201cEarly results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)\u201d at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 – June 2, 2026, in Chicago, IL. \u00a0 Presentation Details: Title: Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Presenting author: Shiraj Sen, MD. PhD., NEXT Oncology Dallas, TX Session: … <\/p>\n

Continue reading “Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-953415","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract \u201cEarly results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)\u201d at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 – June 2, 2026, in Chicago, IL. \u00a0 Presentation Details: Title: Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Presenting author: Shiraj Sen, MD. PhD., NEXT Oncology Dallas, TX Session: … Continue reading "Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-21T14:18:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NDAwNSM3NTQ3NDYxIzIxODEyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting\",\"datePublished\":\"2026-04-21T14:18:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/\"},\"wordCount\":807,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NDAwNSM3NTQ3NDYxIzIxODEyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/\",\"name\":\"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NDAwNSM3NTQ3NDYxIzIxODEyODA=\",\"datePublished\":\"2026-04-21T14:18:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NDAwNSM3NTQ3NDYxIzIxODEyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5NDAwNSM3NTQ3NDYxIzIxODEyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - Market Newsdesk","og_description":"DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract \u201cEarly results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)\u201d at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 – June 2, 2026, in Chicago, IL. \u00a0 Presentation Details: Title: Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Presenting author: Shiraj Sen, MD. PhD., NEXT Oncology Dallas, TX Session: … Continue reading \"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-21T14:18:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NDAwNSM3NTQ3NDYxIzIxODEyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting","datePublished":"2026-04-21T14:18:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/"},"wordCount":807,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NDAwNSM3NTQ3NDYxIzIxODEyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/","name":"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NDAwNSM3NTQ3NDYxIzIxODEyODA=","datePublished":"2026-04-21T14:18:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NDAwNSM3NTQ3NDYxIzIxODEyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5NDAwNSM3NTQ3NDYxIzIxODEyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/953415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=953415"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/953415\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=953415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=953415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=953415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}